Work

Phase I study of the PARP inhibitor olaparib (O) in combination with carboplatin (C) in BRCA1/2 mutation carriers with breast (Br) or ovarian (Ov) cancer (Ca).

Year: 2011

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2011.29.15_suppl.2520

Authors: J. Lee, C. M. Annunziata, L. M. Minasian, J. Zujewski, S. A. Prindiville, H. L. Kotz, J. Squires, N. D. Houston, J. J. Ji, M. Yu, J. H. Doroshow, E. C. Kohn

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2243816036

Cites:

Cited by: 24

Related to: 10